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Abstract
Context: Pheochromocytoma is a rare disease but with high mortality if it is not being diagnosed early. Several
biochemical tests with high accuracy have been obtained, but the clinical threshold for request of these tests is not
determined clearly.
Objectives: To determine the Likelihood Ratios of clinical symptoms and signs in diagnosing pheochromocytoma.
And also meta-analysis of their sensitivity in this disease.
Data sources: MEDLINE was searched for relevant English-language articles dated 1960 to February 2014.
Bibliographies were searched to find additional articles.
Study selection: We included original studies describing the sensitivity and/or likelihood ratios of signs and
symptoms in clinical suspicion of pheochromocytoma. Their method of diagnosis should have been based on
pathology. We excluded specific subtypes or syndromes related to pheochromocytoma, or specific ages or gender.
Also we excluded studies before 1993 (JNC5) which no definition of hypertension was presented. 37 articles were
chosen finally.
Data extraction: Two authors reviewed data from articles independently and gave discrepancies to third author for
decision. The aim was extraction of raw numbers of patients having defined signs or symptoms, and draw 2 × 2
tables if data available. We meta-analyzed sensitivities by Statsdirect and Likelihood Ratios by Meta-disc soft wares.
Because our data was heterogeneous based on I2 > 50 % (except negative Likelihood ratio of hypertension), we
used random effect model for doing meta-analysis. We checked publication bias by drawing Funnel plot for each
sign/symptom, and also Egger test.
Data synthesis: The most prevalent signs and symptoms reported were hypertension (pooled sensitivity of 80.7 %),
headache (pooled sensitivity of 60.4 %), palpitation (pooled sensitivity of 59.3 %) and diaphoresis (pooled sensitivity of
52.4 %). The definition of orthostatic hypotension was different among studies. The sensitivity was 23–50 %.
Paroxysmal hypertension, chest pain, flushing, and weakness were the signs/symptoms which had publication bias based
on Funnel plot and Egger test (P value < 0.05). Seven of the articles had control group, and could be used for calculating
LR of signs/symptoms. Diaphoresis (LR+ 2.2, LR-0.45), Palpitation (LR+ 1.9, LR-0.52) and headache (LR+ 1.6, LR-0.24) were
significant symptoms in clinical diagnosis of pheochromocytoma. Other signs and symptoms had been reported in only
one study and could not have been meta-analyzed. Classic triad of headache, palpitation and diaphoresis in hypertensive
patients had the LR+ 6.312 (95 % CI 0.217–183.217) and LR-0.139 (95 % CI 0.059–0.331). Surprisingly, hypertension was not
important in clinical suspicion of pheochromocytoma, and even normotension increased the probability of the disease.
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Conclusions: By available data, there is no single clinical finding that has significant value in diagnosis or excluding
pheochromocytoma. Combination of certain symptoms, signs and para-clinical exams is more valuable for physicians.
Further studies should be done, to specify the value of clinical findings.Until that time the process of diagnosis will be
based on clinical suspicion and lab tests followed by related imaging.
Keywords: Pheochromocytoma, Likelihood ratio, Clinical exam, Sensitivity, Specificity
Background
Clinical scenario
Case 1: A 35 year old woman was referred by her
family physician because of recurrent spells of
headache, dizziness, and sweating since 6 months ago.
She had also experienced dyspnea and palpitation
followed by chest discomfort. Each time, she was
admitted to the hospital with high blood pressure and
heart rate. But the physical exam between attacks was
normal.
Case 2: A 50 year-old man came to his family physician
with moderate bitemporal headache. On physical exam,
his blood pressure was 170/100 mmHg and pulse rate
was 70. He had no chest pain, dyspnea or blurred
vision. He had experienced such headaches in the last
6 months about once a month.
Why is this question important?
Pheochromocytoma is a rare tumor with an annual inci-
dence of 1–4/106 population [1]. It is popular for causing
hypertension; however, It is an uncommon cause of hyper-
tension, estimated to occur in approximately 0.1 to 1 % of
hypertensive patients [1, 2, 3, 4]. It is suggested that most
doctors meet only one patient with pheochromocytoma in
their working lifetime and a large general hospital admits-
on average- one such patient annually [3]. Despite the low
frequency, pheochromocytoma is fascinating and challen-
ging to clinicians because it has lethal potential if un-
treated, and possible long term cure -in the majority- if
diagnosed and treated surgically. Clinical awareness of this
tumor should be stressed because 1) Surgical removal is
curative in more than 90 % of patients (The 5-year patient
survival after removal of benign pheochromocytoma has
been ranged from 84 to 96 %) [5], 2) Tumor excision has
significant effect on hypertension, the most important
cause of pheochromocytoma related mortality and mor-
bidity. In the follow up of surgeries, it has been shown that
about 60 % of patients became normotensive [3, 6–8]. In
patients with persistent hypertension after surgery, the
mean arterial pressure decreased significantly [6] and was
controlled better with anti-hypertensive drugs [9]; hyper-
tensive crises disappeared after surgery [9, 10]; and
hypertension-related complications regressed significantly
[10], 3) Biochemical testing and imaging together have
high accuracy in detection of the disease 4) Some drugs
and in particular, anesthetic agents may potentiate the
life-threatening effects on the heart and circulation of cat-
echolamines secreted by this tumor, and 5) If it is left un-
treated, fatal complications often ensue, most of which are
related to hypertension (In a series of autopsy from the
Mayo Clinic that spanned 50 years, 75 % of the cases were
undiagnosed during life, although they were symptomatic)
[11]. Thus, early clinical diagnosis of pheochromocytoma
is imperative, to allow clinicians to efficiently complete
further investigations and initiate appropriate treatment
with the goal of minimizing morbidity and mortality.
P.F. Plouin studied 2585 hypertensive patients to find
out the value of clinical triad-headache, palpitation and
diaphoresis, in the diagnosis of pheochromocytoma [12].
He found positive Likelihood ratio (LR) of 14.6 and
negative likelihood ratio of 0.1 for the triad of symptoms.
It showed that clinical picture can predict the probability
of the pheochromocytoma to a good level. From that
time, this triad became the base of clinical suspicion for
endocrinologists to further work up to detect pheochro-
mocytoma. But pheochromocytoma shows many other
symptoms and signs which may have additional benefits
for clinical diagnosis. We did a systematic review in
order to define the value of each piece of the clinical pic-
ture to identify patients with pheochromocytoma whom
further diagnostic tests are indicated.
Pathophysiology and clinical presentation of
pheochromocytoma
First described in 1886 by Fränkel, pheochromocyto-
mas are tumors derived from the chromaffin cells of
the embryonic neural crest [1]. Chromaffin cells are
post-ganglionic sympathetic neurons which produce
catecholamines. When fresh tissue samples are oxi-
dized with certain fixatives, their catecholamine con-
tent is stained dark grey-brown (“peso” in Greek).
These cells are mainly located in the adrenal medulla
(in fact, approximately 85–95 % of pheochromocyto-
mas are located in the adrenal medulla) [2, 13]. Tu-
mors arising from extra-adrenal chromaffin cells are
termed paragangliomas and they can be found along
the paravertebral and para-aortic axes (sympathetic
paraganglia have a neck-to-pelvis distribution, while
parasympathetic paraganglia are found almost
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exclusively in the neck and skull base, along the
branches of glossopharyngeal and vagus nerve).
Although about 4 % of adrenal masses incidentally
found are known to be pheochromocytoma [2], this
tumor is popular for its catecholamine secretion, and
symptoms the catecholamines produce. The most cate-
cholamines secreted are epinephrine, norepinephrine
and dopamine. Figure 1 illustrates the catecholamine
metabolism in normal human cells. Normal adrenal
glands contain mostly epinephrine. Most pheochromo-
cytomas secrete predominantly norepinephrine; and
about 15 % secrete predominantly epinephrine. Dopa-
mine β-hydroxylase, responsible for converting dopa-
mine to norepinephrine, may be missing in immature
tumors; Thus, the presence of a tumor secreting pre-
dominantly dopamine indicates a higher probability of
malignancy. Pheochromocytoma has been called the
“Great Mimic” since its manifestations can resemble so
many other conditions, which may confuse clinicians
[14]. The clinical presentation varies, ranging from an
adrenal incidentaloma to hypertensive crises with associ-
ated cerebrovascular or cardiac complications [15]. The
vast majority of symptoms and signs are attributable to
the excess of catecholamines released by tumors
continuously or paroxysmally. The most leading
catecholamine-related sign for clinicians to suspect
pheochromocytoma is hypertension. Related to hyper-
tension, four patterns of blood pressure are seen. Sus-
tained hypertension, paroxysmal hypertension, sustained
hypertension with paroxysms, and normotension. This
variation is somehow related to the catecholamine pre-
dominantly secreted by the tumor. The catecholamines
exhibit different effects on different catecholamine re-
ceptors; typically, norepinephrine-mediated stimulation
of α-receptors leads to vasoconstriction whereas epi-
nephrine stimulates β2-receptors, causing vasodilata-
tion. Subjects with predominantly norepinephrine-
secreting pheochromocytoma (noradrenergic pheno-
type) develop sustained hypertension more frequently
than subjects with predominantly epinephrine-
producing pheochromocytomas (adrenergic pheno-
type) who present more often with paroxysmal symp-
toms. Dopamine-producing tumors often present with
normotension [14]. Paroxysmal release of catecholamines
constitutes the characteristic classic triad of episodic head-
ache, sweating, and palpitations which is known as "an at-
tack". In some patients, a particular stimulus triggers an
attack. Anesthesia and tumor manipulation are the most
well-known triggers for catecholaminergic crisis; pos-
itional change, exercise, and various medications (e.g.
TCAs, opiates, metoclopramide and radiographic contrast
agents) are other possible precipitating factors. In others,
no clearly defined precipitating event can be found, and
the episodes occur in a random pattern.
In addition to the classic triad, patients often experience
other symptoms such as anxiety, dyspnea, chest, abdom-
inal or flank pain, nausea and vomiting, tremor, flushing,
dizziness, visual symptoms such as blurred vision, and
paresthesia. On the other hand, persistent vasoconstric-
tion in patients with pheochromocytoma declines the
blood volume leading to orthostatic hypotension [16]. The
sudden out-pouring of epinephrine has been postulated as
causing an elevation in body temperature by a combin-
ation of inducing hypermetabolism and impairing heat
Fig. 1 The catecholamine metabolism in normal human cells
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dissipation as a consequence of cutaneous vasoconstric-
tion [17] (the leading cause of pallor during attacks). Hy-
permetabolism caused by catecholamines can cause
weakness, fatigue and weight loss. Paradoxically, some pa-
tients have diarrhea, whereas others may have
constipation.
Although chronic hypertension can cause cardiovascu-
lar complications, catecholamines directly have toxic ef-
fect on myocardium as well. During attacks different
ECG changes evolve, which are resolved after the sur-
gery. However, chronic exposure to catecholamine can
lead to irreversible myocardial fibrosis [16].
Methods
Literature search
We reviewed Medline database from 1960 to February
2014 by the structured search strategy including both
text word and MeSH term of the following keywords:
pheochromocytoma, diagnosis, physical examination,
medical history taking, sensitivity and specificity, repro-
ducibility of results, observer variation and predictive
value of tests; We limited the results to English language
and humans.1 The results were reviewed by two of the
authors for relevance and quality. The aim was looking
for original articles which reported the sensitivity and/or
specificity of symptoms in patients with pheochromocy-
toma. Then, the results were discussed and the papers
which the authors had disagreement, were given to the
third author for decision about inclusion. We chose the
papers which their method for disease-confirmation was
based on histopathology and the data was extracted be-
fore diagnosis of the disease (in order to resolve recall
bias). We excluded papers which studied a specific sub-
type of pheochromocytoma (e.g. malignant or familial),
or just syndromes that pheochromocytoma was a part of
them (e.g. MEN, Von Hippel Lindau disease). Also, we
excluded the studies on only specific age/gender. More-
over, we reviewed the papers studying the value of bio-
chemical testing in diagnosis of pheochromocytoma (we
thought that these studies more possibly have specificity
of symptoms beside their sensitivity, because of having
control group); if they had clinical data of the patients,
and if they had no clinical relevant data, we sent an
email to the authors and asked for their clinical data if
available. On the other hand, we tracked the references
of review articles to find more original articles. In
addition to electronic search, we did hand-searching
using endocrinology textbooks.
Definitions
We defined hypertension as blood pressure higher than
140/90 mmHg. As this definition was accepted in the
fifth Joint National Committee on Detection, Evaluation,
and Treatment of High Blood Pressure (JNC V) in 1993
[18], we sent emails to the authors of articles published
before this time with no definition for hypertension in
the article and asked if their definition was the same,
and if we got no response, we ommited the article from
analysis. Orthostatic hypotension was defined as a drop
in systolic (20 mmHg) or diastolic (10 mmHg) blood
pressure within 3 min of standing. Finally, because the
definitions were different among the studies which
checked this sign, we separately discussed the articles in
the result section.
Data analysis
After selection of articles for analysis, considering inclu-
sion and exclusion criteria, we extracted the crude num-
bers of patients having symptoms or signs of possible
pheochromocytoma. The symptoms consist of headache,
palpitation and diaphoresis (three parts of the classic
triad), total classic triad, flushing, palor, nausea/vomit-
ing, weakness/fatigue, diarrhea, constipation, dizziness/
vertigo, chest pain, abdominal pain, flank pain, dyspnea,
paresthesias, anxiety, visual symptoms, and tremor. The
signs we looked for, were hypertension and orthostatic
hypotension. We filled the 2 × 2 tables for calculating LR
for the symptoms that we could, and put the sensitivities
together in a separate table. Meta-analysis was done if
possible (number of studies more than one) for LR of
symptoms and signs, and a meta-analysis was performed
for sensitivities separately. Several factors affect distribu-
tion of symptoms and signs in studies, such as distribu-
tion of genders, malignant or benign disease and size of
the tumor, but none of the studies had separated these
factors (so we could not do subgroup analysis or meta-
regression if the data was heterogeneous). We calculated
heterogeneity by drawing Forest plot and I2 test. We
considered heterogeneity as I2 > 50 %. Because our data
was heterogeneous based on I2 (except one), we used
random effect model for doing meta-analysis. We
checked publication bias by drawing Funnel plot for
each sign/symptom, and also Egger test. If the P value in
Egger test is below 0.05, then we considered the data to
have publication bias. Analysis of the sensitivity was
done by Stats-direct software and analysis of the LRs
was done by meta-disc software.
Result
The initial search strategy yielded 4118 results. And the
result of our hand-searching was 13. Based on titles, 238
articles were selected. From the articles which had stud-
ied biochemical diagnosis of pheochromocytoma and we
had sent emails to authors for clinical data, one article
was received (ref 23). From these 238 articles, 31 were
inappropriate type by abstract, 119 original and 88 re-
view articles were extracted. After getting full-text for
checking relevancy and quality analysis, and also
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considering inclusion and exclusion criteria for original
articles, 29 were selected for data extraction. By
reference-tracking, 12 more original articles were found.
Totally 42 articles were considered for analysis. Based
on our definition for hypertension, 4 articles were ex-
cluded because they were done before 1993, and the def-
inition of hypertension was not specified, and there was
no answer to our email for definition. All-but one-of the
studies were based on medical records of the patients;
the study of W. Lai et al. [19] was based on question-
naire from the patients after diagnosis of pheochromocy-
toma, which could make recall bias; so, this study was
excluded from data analysis. Finally, 37 articles were an-
alyzed (Fig. 2).
The characteristics of the articles are shown in Tables 1
and 2. Seven of these articles had control groups; five of
which the control groups were the patients with sus-
pected but excluded pheochromocytoma surgically or by
Fig. 2 Systematic review flow diagram
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Table 1 Studies Assessing Clinical Presentations without control group
Table A (studies without control group)
Source Clinical setting, Years No. of Patients Age, Mean (Range) Gender
(M,F)
Ref
Chung-Yau Lo et al., 2000 Queen Mary hospital, Hong
Kong, China, 1981–1998







M. Mannelli et al., 1999 18 centers from all over Italy,
1978–1997
258 44 (8–84) in female
46(12–79) in male
– [6]
Gennaro Favia et al., 1998 A university endocrine surgery
unit, Italy, 1977–1996
55 41 (10–63) 28,27 [7]
Gunnar Stenstrom et al., 1988 A university hospital, Sweden,
1956–1982
64 45 (15–79) 30,34 [8]
J.W. Lance and Hinterberger, 1976 A University Hospital in Sydney,
Australia
27 9–54 14,13 [15]
Patócs et al., 2004 Faculty ofMedicine, Semmelweis
University in Budapest, Hungary.
1995–2003
41 (20–73) 11,30 [21]
FC Hernandez et al., 2000 UniversityHospital “Virgen de la
Arrixaca”, Murcia,Spain. 1994–1998
57 42 (7–71) 34,23 [22]
Laurence Amar et al., 2005 Referral to a Hypertension
unit, France, 1975–2003
192 44 89,103 [24]
K.C. Loh et al. 1997 Endocrine clinics, Nova Scotia,
Canada, 1986–1995
18 42 (12–81) 3,15 [25]
Charles AG Proye et al., 1994 3 medical centers, France,
1951–1992
310 – – [26]
P.F. Plouin et al., 1997 A hospital in Paris, France,
1975–1994
129 42.6 (13–80) 63,66 [27]
Roger R. Perry et al., 1990 Surgery branch of National
cancer instate, Maryland,
USA, 1982–1989




TD O'halloran et al., 2001 St. Vincent hospital Ireland,
1950–1997
33 40.6 (12–74) 9,24 [29]
Aguilo et al., 1991 University hospital, Puerto Rico,
1970–1990
24 (19 diagnosed clinically and
5 post-mortem)
43.2 (17–74) 14,10 [30]
J.E. Thomas et al., 1966 Mayo clinic, USA.1945–1964 100 (97 in life and 3 autopsy) 41 (4–67) 42,58 [31]
Robert Kopetschke et al., 2009 4 endocrine centers, Germany,
1973–2007
183 12–85 – [32]
C. Charles et al. 1984 A university hospital, Jamaica,
1963–1983
16 38 (13–66) 8,8 [33]
Wei-ber Liao et al., 2000 Chang Gung memorial hospital,
Taiwan, 1993–1997
25 49 (16–68) 14–11 [34]
Joyce SY Yau et al. 2010 endocrine clinics of the Kowloon
West Cluster hospitals, china.
1994–2003
17 (19 at first. 2 lost to follow up) 47 (17–72) 6,11 [35]
Van Duinen et al. 2010 Leiden university medical center,
Netherland, 1975–2008
28 patients whom the
pheochromocytoma was
diagnosed based on signs
and symptoms
47 – [36]
Bernard Goldny et al., 2001 Department of General Surgery
of the University of Munster Hospital,
Germany. 1967–1998
133 41.4 (2–75) 68,65 [37]
I.M. Modlin et al. 1979 A number of hospitals, England,
1955–1976
72 (58 diagnosed in life) – [38]
E. J. Ross and Griffith 1989 3 hospitals, London, England,
1952–1982
54 12–74 16,38 [39]
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Table 1 Studies Assessing Clinical Presentations without control group (Continued)
Ulf Niemann et al., 2002 University hospital, Germany.
1974–2000
87 49 (14–78) 38,49 [40]
Takyo Noshiro et al., 2000 Tohoku UniversitySchool of
Medicine, Sendai, Japan.
1957–1995
95 (2 autopsy) – 43,52 [41]
Richard E. Goldstein et al.,1999 2 medical centers, Tennessee,
USA, 1950–1998
84 42 (9–79) 38,66 [42]
Khoram manes et al. 2005 SahlgrenskaUniversity Hospital.
western region of Sweden.
1950–1997
121 47 (7–71) 53,68 [43]
N. Sharma et al., 2001 Tertiary care hospital, Chandigarh,
India, 1989–1996
30 24 (17–31) 17, 13 [44]
Masky P et al. 2012 Tribhuvan University Teaching
Hospital, Maharajgunj, Kathmandu,
Nepal. 2008–2011
12 36 (12–65) 5,7 [45]
Table 2 Studies Assessing Clinical Presentations with control group
Table B (studies with
control group)





Plouin et al., 1981 Hypertension service,
saint-Joseph hospital,
Paris, France, from 1977
2585 hypertensive patients
(11 of them were found to
have pheochromocytoma)
33–60 1443,1142 All of the 2585 patients
are considered control
group as the proportion of
pheochromocytoma is 0.4 %
[12]
Peter P. Stein et al. 1991 Yale university school of
medicine, USA.







Henry R. Black et al. 1984 11 new England hospitals,
USA, 1962–1980
53 patients (60 first. 5 excluded
because of finding based on
predisposition genetic factor.









P.F. Plouin et al., 1988 Hypertension departments




– Yes (21 patients with
essential hypertension)
[20]





































a 28 (a pheochromocytoma was considered but excluded if any 1 of several conditions were met: 1) repeatedly normal urine collections for catecholamine
metabolites (VMA or MN) and urine free catecholamines (UFC) and no diagnosis of pheochromocytoma after 2 years of follow up; 2) negative imaging studies (CT,
MRI or MIBG) and no diagnosis of pheochromocytoma after 2 years of follow up; 3) resolution of the clinical symptoms and/or alternate diagnosis, explaining the
symptoms, established.)
b Patients highly suspected to have pheochromocytoma in whom the diagnosis was ruled out by negative arteriograms and no evidence of disease after at least
18 months follow-up
c 213 patients screened for resistant or markedly accelerated hypertension, paroxysmal hypertension, and ‘flushes’ and, in a small proportion, for adrenal
incidentaloma or genetic predisposition to pheochromocytoma. in who diagnose was not confirmed by long-term follow-up or use of imaging techniques
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follow-up, and in two others, the control group was
hypertensive patients. In addition, in these two articles,
the total population was hypertensive patients not the
general population. So, data analysis of these two was
done separately from the other five.
Based on our definition of heterogeneity, all of our
data in groups were heterogenous (except negative LR of
hypertension with I2 of 43.2 %); so we did meta-analysis
with random effect. Number of studies which had re-
ported sensitivity of signs/symptoms, pooled sensitivity
with method of random effect and its 95 % confidence
intervals are shown in Table 3.
The definition of orthostatic hypotension was different
among studies. The sensitivity based on the definition is
shown in Table 4.
Based on funnel plot and Egger test, paroxysmal
hypertension, chest pain, flushing, and weakness were
the signs/symptoms which had publication bias.
As we mentioned before, seven of the articles had con-
trol group, and therefore could be used for calculating
LR of signs/symptoms. Seven of the symptoms were
evaluated in these articles: palpitation, diaphoresis, clas-
sic triad, hypertension, weakness/fatigue, anxiety and
flushing. We draw the 2 × 2 table for each of the symp-
toms/signs and meta-analyzed the LRs with meta-disc
software (Table 5).
Discussion
The main purpose of this article was defining sensitivity
and—if possible-LR of signs and symptoms in diagnosis
of pheochromocytoma. We used the search strategy of
“Rational Clinical Examination” for collecting articles in
Medline from 1960 to 2014; and used reference tracking
of review articles to find more relevant original articles.
In addition to electronic search, we did hand-searching
using endocrinology textbooks. The result of this search
strategy was 37 articles. From 6 of these articles, we
could fill the 2 × 2 table of LRs.
For evaluating the possibility of doing meta-analysis
for our data, first we calculated heterogeneity of differ-
ent symptoms, which all were heterogeneous according
to definition of heterogeneity based on I2 (except nega-
tive LR of hypertension with I2 of 43.2 %). Because of
heterogeneity of data, we used random effect model for
meta-analysis. For evaluating publication bias we used
Egger test, which the P-value < 0.05 was considered sig-
nificant and so the data was considered to have publica-
tion bias. This was true for 4 of the symptoms:
paroxysmal hypertension, chest pain, flushing and
weakness.
The meta-analysis of positive and negative LRs for
symptoms and signs was done. Therefore, palpitation
with positive LR of 1.888 (95 % CI 1.161–3.073) and
negative LR of 0.518 (0.333–0.806), diaphoresis with
positive LR of 2.184 (1.411–3.382) and negative LR of
0.451 (0.310–0.657) and headache with positive LR of
1.607 (1.124–2.297) and negative LR of 0.240 (0.094–
0.613) were the symptoms useful in differentiating pheo-
chromocytoma from other similar diseases. In addition,
not having the classic triad had the LR of 0.139 (0.059–
0.331) (Table 5). One was included in confidence inter-
val of a number of LRs, but because of asymmetry of the
intervals, the numbers could be considered clinically sig-
nificant. These, include classic triad with the positive LR
of 6.312 (0.217–183.217), hypertension with the positive
LR of 0.762 (0.562–1.033), anxiety with the positive LR
of 1.127 (0.500–2.541), and flushing with the negative
LR of 1.466 (0.754–2.850). Among our data only one
feature proved to be homogenous: negative LR of hyper-
tension (LR-of 1.682 with 95 % confidence interval of
1.093–2.589).
Based on Plouin study in 1981 on 2585 hypertensive
patients, classic triad of headache, palpitation and dia-
phoresis has the LR of 14.63 (positive) and 0.1 (negative)
in patients with hypertension for diagnosis of






Headache 25 60.4 53.2–67.4
Palpitation 19 59.3 51.9–66.6
Diaphoresis 28 52.4 0.457–59.1
Triad 8 58 28.6–84.7
Spells 7 57.5 33.9–79.3
HTN(total) 23 80.7 74.7–85
HTN(sustained) 9 36.3 20.5–53.9




Chest pain 16 17.3 11.4–24.2
Abdominal pain 11 16.5 11.9–216
Flank pain 2 5.2 20.7–9.6
Dyspnea 10 23.4 16.2–31.5
Anxiety 14 28.6 22.9–34.7
Constipation 4 13.8 32.2–29.9
Diarrhea 2 4 0.8–9.4
Dizziness 11 17.7 13.5–22.3
Flushing 14 15 9.3–21.7
Pallor 7 31.6 17.3–47.9
Nausea/Vomiting 14 21.2 16–26.7
Paresthesia 4 13.6 10–17.8
Tremor 10 20.2 14.5–26.6
Visual disturbance 7 9.6 5.6–14.6
Weakness/Fatigue 8 23.8 15.7–33.9
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pheochromocytoma [12]. We found similar negative LR
(0.139) for classic triad but the result of positive LR was
different (6.3). When we looked at 2 studies of Plouin
for evaluating classic triad in diagnosis of pheochromo-
cytoma, [12, 20] we noticed some differences (Table 6).
As shown on the table, the most significant difference
between two studies is the ratio of false negative results
to all negative results (4/14 vs. 1/2414). An explanation
can be the precedence of the first study (1981) with lar-
ger sample size [12]. At that time thinking about the
triad symptoms was not routine and evidence-based. So,
it is possible that asking about them was not done in a
series of patients and this group was classified as “not
having the symptoms”. So, the ratio of patients that ap-
parently didn’t have the symptoms and finally diagnosed
as “having pheochromocytoma” was increased (As the
study was retrospective and based on patients’ files).
Hypertension is the most famous sign among physi-
cians for clinical suspicion of pheochromocytoma. What
we found was somehow different. We found positive LR
of 0.762 (0.562–1.033) with an asymmetry through
below 1 (means that hypertension decreases the prob-
ability of pheochromocytoma), and negative LR of 1.682
(1.093–2.589) with heterogeneity below 50 % (means
homogeneity of data and so fixed effect meta-analysis),
which shows that normotension increases the probability
of pheochromocytoma. Our explanation is that may be
in patients without hypertension the threshold to think
about and refer for further analysis of pheochromocy-
toma is higher for clinicians, and so more patients finally
would be proved having pheochromocytoma.
Some of the symptoms were only reported in Stein’s
article [16]. Pallor, dyspnea, paresthesia, and orthostatic
hypotension were the symptoms and signs which their
presence increases the likelihood of pheochromocytoma;
whereas diarrhea, constipation, dizziness, chest pain and
tremor were the symptoms and signs which their pres-
ence decreases the likelihood of pheochromocytoma.
Table 5 Pooled estimation of LR for symptoms and signs of pheochromocytoma
Sign/symptom Number of studies LR+ (95%CI) LR- (95%CI)
Palpitation 2 1.888 (1.161–3.073) 0.518 (0.333–0.806)
Diaphoresis 2 2.184 (1.411–3.382) 0.451(0.310–0.657)
Classic triada 2 6.312 (0.217–183.217) 0.139 (0.059–0.331)
Hypertension 5 0.762 (0.562–1.033) 1.682 (1.093–2.589) fixed effect
Weakness/fatigue 2 1.123 (0.658–1.919) 0.964 (0.772–1.205)
Anxiety 2 1.127 (0.500–2.541) 0.933 (0.635–1.369)
Headache 2 1.607 (1.124–2.297) 0.240 (0.094–0.613)
Flushing 2 0.283 (0.058–1.391) 1.466 (0.754–2.850)
Spells 1b 0.93 1.16
Pallor 1 4.667 0.718
Diarrhea 1 0.311 1.188
Constipation 1 0.156 1.230
Dizziness 1 0.431 1.493
Paresthesia 1 1.867 0.933
Tremor 1 0.560 1.096
Orthostatic hypotensionc 1 1.885 0.792
a In all but classic triad, the control group was highly suspected but ruled out pheochromocytoma. In the classic triad, the control groups were patients
with hypertension
b These symptoms were evaluated in Stein’s article.16
c The definition of orthostatic hypotension in Plouin study was falling SBP > 10 mmHg, and the control group was patients with essential hypertension
Table 4 Sensitivity of orthosthatic hypotension based on different definitions in studies
Study (number of patients) Definition of OHa Sensitivity (%)
M. Mannelli et al. (156) falling SBP > 30 mmHg or falling DBP > 20 mmHg 23
N. Sharma et al. (30) fall in SBP > 20 mmHg 50
Baguet et al. (41) [48] fall in SBP > 20 or fall in DBP > 10 1 min after standing 36.6
Plouin et al. (39) fall in SBP > 10 mmHg 36
Abbreviations: aOH othostatic hypotension, SBP systolic blood pressure, DBP diastolic blood pressure
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Diarrhea and constipation are non-specific symptoms re-
lated to pheochromocytoma; so, their incidence is not
valuable accordingly.
The LRs of orthostatic hypotension was studied in
Plouin article [20]. The control group were patients with
essential hypertension and the definition of orthostatic
hypotension was falling systolic blood pressure more
than 10 mmHg after standing. The positive LR 1.885
(0.710–5.003) and the negative LR 0.792 (0.579–1.083)
were calculated. The value of triad plus orthostatic
hypotension was studied too. When considering this
combination, the sensitivity was decreased from 89 %
(considering triad alone) to 30 %, and the specificity was
increased from 67 to 95 %. (LR + = 6.462 (0.901–46.325),
LR-= 0.727 (0.578–0.915).
By drawing the Funnel plot for each sign/symptom
and doing Egger test for assessing publication bias, par-
oxysmal hypertension, chest pain, flushing and weakness
were the signs/symptoms which had publication bias
based on our definition. So, these items reasonably
should be excluded from our final report.
At last, when we look at the table of LRs, it seems that
no single sign or symptom alone is helpful in diagnosis
of pheochromocytoma. Rather, the combination (such as
the classic triad) can be probably important for this aim.
Despite flushing and pallor had significant positive LRs
and headache had significant negative LR, these were
evaluated in only one study and additional studies
should be done for more accuracy. Studying the triad in
hypertensive patients decrease the spectrum bias and ap-
proximates the LRs to reality in clinical setting. Accord-
ing to Plouin’s study (11 pheochromocytoma in 2585
hypertensive patients), the probability of pheochromocy-
toma in hypertensive patients with classic triad becomes
2.6 %, compared with 0.4 % in hypertensive patients
[12]. By experts’ consensus, this number could be high
enough for continuation of evaluating the disease. On
the other hand, the probability of pheochromocytoma in
hypertensive patients without classic triad becomes
0.05 % (compared with 0.4 % in patients with classic
triad). So it seems reasonable to clinically rule out the
disease by this data.
Limitations
The limitations of our study were looking for English arti-
cles only, and using only PubMed for our search. For
compensation of this limitation, we used reference track-
ing for expanding the results. This was done till we
reached the point that the articles we were finding became
duplicated. Also we looked at articles which aimed to
diagnose pheochromocytoma biochemically (we hoped to
find control groups and therefore could calculate LR).
The other problem was verification bias. Patients with
known signs/symptoms are usually referred for evaluation
of pheochromocytoma. Patients with less common pre-
sentations are less evaluated and this overestimates sensi-
tivity and underestimates specificity of the findings.
Because most of the studies were done in referral centers,
the verification bias would further increases. Doing the
studies in tertiary referral centers also cause spectrum
bias, because the prevalence of pheochromocytoma defers
from the general population in this setting. In some of the
studies found, the prevalence of pheochromocytoma in
the population studied was reported. This, has a range of
1.5–6.7 % (compared to prevalence of 1–4 × 10−6 in the
general population) [21–23].
An important point is the paucity of studies about
value of clinical presentation regarding pheochromocy-
toma. Because of heterogeneity of most of the clinical
studies and wide confidence interval of results, add-
itional studies are recommended to narrow the confi-
dence intervals and increase the precision of the results.
Scenario resolution
Case 1: As the essential hypertension is most
commonly seen in middle aged population, the
presence of paroxysmal hypertension in a young patient
leads us to pathological conditions such as
pheochromocytoma. The presence of classic triad of
headache, palpitation and sweating raises the clinical
suspicion 6 times. The other symptoms (dizziness,
chest pain, dyspnea) are not independent. So we cannot
simply multiply them to calculate the final LR. By
considering the value of signs and symptoms, we
decided to move forward in our evaluation. The level of
urine catecholamines was increased. Imaging showed a
3 cm mass in left adrenal gland. The patient was
referred to surgeon for left adrenalectomy. The
pathologist reported chromaffin cells and the diagnosis
of pheochromocytoma was proved. The attacks of the
patient subsided after surgery and the blood pressure
became stable during 2 years of follow up.
Case 2: The patient was a known hypertensive patient
from 5 years ago on anti-hypertensive drugs. Symptoms
of emergent hypertension were asked from the patient
Table 6 Two studies of P.F. Plouin for evaluating classic triad in diagnosis of pheochromocytoma
Authors, number of patients and control group TP FP FN TN
P.F. Plouin et al. 1988, N = 39/21essential HTN 35 7 4 14
Plouin et a 198 l, N = 2585 HTN whose 11 patient had pheochromocytoma 10 160 1 2414
Abbreviations: TP true positive, FP false positive, FN false negative, TN true negative
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(chest pain, blurred vision, hematuria, and headache)
and a complete physical exam was done. Then, he was
given oral anti-hypertensive drugs and observed for
4 h. He was discharged from the Emergency
department and was recommended to visit his family
physician. The absence of classic triad and other parts
of the history made pheochromocytoma less probable.
Conclusions
Bottom line
By available data, there is no single clinical finding that
has significant value in diagnosis or excluding pheochro-
mocytoma. Combination of certain symptoms, signs and
para-clinical exams is more valuable for physicians. Fur-
ther studies should be done, in order to specify the value
of clinical findings-alone or in combination- in favor or
against the diagnosis of pheochromocytoma more accur-
ately, to help us distinguish patients who require more
evaluation, from those who require no further testing.
Until that time the process of diagnosis will be based on
clinical suspicion and lab tests followed by related
imaging.
Endnotes
1This strategy was selected based on the “search strat-
egy for the rational clinical examination-David L. Simel,
1995”.
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